Latest Information Update: 11 Dec 2006
At a glance
- Originator Kissei Pharmaceutical
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 12 Jan 1999 New profile
- 12 Jan 1999 Preclinical development for Thrombosis in Japan (Unknown route)